Login Register Cart 0
Generic placeholder image

Current Organic Synthesis

Editor-in-Chief

ISSN (Print): 1570-1794
ISSN (Online): 1875-6271

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Letter Article

Isolation, Characterization, and Docking Studies of (Z)-Isopropyl 7-((1R, 2R, 3R, 5S)- 2-((1E, 3Z)-3-Fluoro-4-Phenoxybuta-1, 3-Dienyl)-3,5-Dihydroxycyclopentyl) Hept-5- Enoate, an Impurity of Tafluprost

Author(s): Rama Mohana Reddy Jaggavarapu, Venkatanarayana Muvvala*, Ventakareddy Ghojala and Ravi Kumar Cheedarala*

Volume 19, Issue 1, 2022

Published on: 09 December, 2020

Page: [10 - 15] Pages: 6

DOI: 10.2174/1570179417666201209141222

Price: $65

Abstract

Introduction: The origin, isolation, and characterization of (Z)-isopropyl 7-((1R, 2R, 3R, 5S)-2-((1E, 3Z)-3-fluoro-4-phenoxybuta-1, 3-dienyl)-3, 5-dihydroxycyclopentyl) hept-5-enoate, an impurity found in the preparation of an anti-glaucoma agent-Tafluprost has been described in this study.

Materials and Methods: Further, an enantiospecific synthesis of (Z)-isopropyl 7-((1R, 2R, 3R, 5S)-2-((1E, 3Z)- 3-fluoro-4-phenoxybuta-1, 3-dienyl)-3, 5-dihydroxycyclopentyl) hept-5-enoate has been revealed using deoxofluorination as a key transformation of the strategy.

Results and Discussions: Moreover, the impurity showing anti-glaucoma properties in docking studies with respect to bimatoprost has been described.

Conclusion: The extention of our work towards docking studies and the present impurity molecule showed almost the same biological activity with respect to Tafluprost.

Keywords: Glaucoma, (Z)-isopropyl 7-((1R, 2R, 3R, 5S)-2-((1E, 3Z)-3-fluoro-4-phenoxybuta-1, 3-dienyl (-3, 5-dihydroxycyclopentyl) hept-5-enoate, prostaglandins, tafluprost, docking studies.

« Previous Next »
Graphical Abstract

[1]
Nakamura, C.; Kawasaki, N.; Miyataka, H.; Jayachandran, E.; Kim, I.H.; Kirk, K.L.; Taguchi, T.; Takeuchi, Y.; Hori, H.; Satoh, T. Synthesis and bio- logical activities of fluorinated chalcone derivatives. Bioorg. Med. Chem., 2002, 10(3), 699-706.
[http://dx.doi.org/10.1016/S0968-0896(01)00319-4] [PMID: 11814858]
[2]
Lal, G.; Pez, G.P.; Pesaresi, R.J.; Prozonic, F.M. Bis(2- methoxyethyl)aminosulfur Trifluoride: A New Broad-Spectrum Deoxofluorinating Agent with Enhanced Thermal Stability. Chem. Commun. (Camb.), 1999, 215-216.
[http://dx.doi.org/10.1039/a808517j]
[3]
Lal, G.S.; Lobach, E.; Evans, A. Fluorination of thiocarbonyl compounds with Bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-fluor reagent): A facile synthesis of gem-difluorides. J. Org. Chem., 2000, 65(16), 4830-4832.
[http://dx.doi.org/10.1021/jo000020j] [PMID: 10956459]
[4]
Ye, H.; Tong, J.; Liu, J.; Lin, W.; Zhang, C.; Chen, K.; Zhao, J.; Zhu, W. Combination of gemcitabine-containing magnetoliposome and oxaliplatin- containing magnetoliposome in breast cancer treatment: A possible mecha- nism with potential for clinical application. Oncotarget, 2016, 7(28), 43762-43778.
[http://dx.doi.org/10.18632/oncotarget.9671] [PMID: 27248325,]
[5]
Cohen, P.R. Genital Rejuvenation: The Next Frontier in Medical and Cosmetic Dermatology. Dermatol Online, 2018, 24(9), 13030.
[PMID: 30677826]
[6]
Quigley, H.A.; Broman, A.T. The number of people with glaucoma world- wide in 2010 and 2020. Br. J. Ophthalmol., 2006, 90(3), 262-267.
[http://dx.doi.org/10.1136/bjo.2005.081224] [PMID: 16488940]
[7]
Distelhorst, J.S.; Hughes, G.M. Open-angle glaucoma. Am. Fam. Physician, 2003, 67(9), 1937-1944.
[PMID: 12751655]
[8]
Doucette, L.P.; Walter, M.A. Prostaglandins in the eye: Function, expression, and roles in glaucoma. Ophthalmic Genet., 2017, 38(2), 108-116.
[http://dx.doi.org/10.3109/13816810.2016.1164193] [PMID: 27070211]
[9]
Gordon, M.O.; Kass, M.A. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch. Ophthalmol., 1999, 117(5), 573-583.
[http://dx.doi.org/10.1001/archopht.117.5.573] [PMID: 10326953]
[10]
Bean, G.W.; Camras, C.B. Commercially Available Prostaglandin Analogs for the Reduction of Intraocular Pressure: Similarities and differences. Surv. Ophthalmol., 2008, 53, 69-S84.
[http://dx.doi.org/10.1016/j.survophthal.2008.08.012]
[11]
Gursoy, A.; Kamil, G.; Atilla, B.; Didem, S.C.; Serdal, K. Şahap. A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients. Ophthalmologica, 2008, 222, 88-95.
[12]
Camras, C.B. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol., 2002, 133(5), 732-733.
[http://dx.doi.org/10.1016/S0002-9394(02)01396-X] [PMID: 11992888]
[13]
Cantor, L.B. Bimatoprost: a member of a new class of agents, the prostam- ides, for glaucoma management. Expert Opin. Investig. Drugs, 2001, 10(4), 721-731.
[http://dx.doi.org/10.1517/13543784.10.4.721] [PMID: 11281821]
[14]
Angeli, A.; Supuran, C.T. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018). Expert Opin. Ther. Pat., 2019, 29(10), 793-803.
[http://dx.doi.org/10.1080/13543776.2019.1661992] [PMID: 31462124]
[15]
Holmstrom, S.; Buchholz, P.; Walt, J.; Wickstrøm, J.; Aagren, M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr. Med. Res. Opin., 2005, 21(11), 1875-1883.
[http://dx.doi.org/10.1185/030079905X65600] [PMID: 16307709]
[16]
Moussa Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle- controlled phase III clinical studies. J. Ophthalmol., 2018, 0, 1-7.
[17]
Nakajima, T.; Matsugi, T.; Goto, W.; Kageyama, A.M.; Mori, N. Matsumu- ra, Y.; Hara, H. New Fluoroprostaglandin F2a Derivatives with Prostanoid FP- Receptor Agonistic Activity as Potent OcularHypotensive Agents. Biol. Pharm. Bull, 2003, 26(12), 1691-1695.
[http://dx.doi.org/10.1248/bpb.26.1691.]
[18]
Matsumura, Y.; Mori, N.; Nakano, T.; Sasakura, H.; Matsugi, T.; Hara, H.; Morizawa, Y. Synthesis of the highly potent prostanoid FP receptor agonist, AFP-168: a novel 15-deoxy-15,15-difluoroprostaglandin F2a derivative. Tetrahedron Lett., 2004, 45, 1527-1529.
[http://dx.doi.org/10.1016/j.tetlet.2003.12.029]
[19]
Sreenivasulu, J.; Venkata Ramana, P.; Sampath Kumar Reddy, G.; Rakesh, M. Nagaraju, ChV.; Thirumalai Rajan, S.; Eswaraiah, S.; Kishore, M.; Ra- makrishna, M. Development of Novel RP-HPLC Method for Separation and Estimation of Critical Geometric Isomer and Other Related Impurities of Tafluprost Drug Substance and Identification of Major Degradation Com- pounds by Using LC-MS. J. Chromatogr. Sci., 2016, 54(8), 1397-1407.
[http://dx.doi.org/10.1093/chromsci/bmw086] [PMID: 27226462]
[20]
Heureux, L.; Beaulieu, A.; Bennett, F.; Bill, C.; Clayton, D.R.; LaFlamme, S.; Mirmehrabi, F.; Tadayon, M.; Tovell, S.; Couturier, D. Aminodifluorosulfinium Salts: Selective Fluorination Reagents with Enhanced Thermal Stability and Ease of Handling. J. Org. Chem., 2010, 75, 3401-3411.
[http://dx.doi.org/10.1021/jo100504x] [PMID: 20405933]
[21]
Middleton, W.J. New fluorinating reagents. Dialkylaminosulfur fluorides. J. Org. Chem., 1975, 40, 574-578.
[http://dx.doi.org/10.1021/jo00893a007]
[22]
Beaulieu, F.; Beauregard, L.P.; Courchesne, G.; Couturier, M.; LaFlamme, F.; L’Heureux, A. Aminodifluorosulfinium tetrafluoroborate salts as stable and crystalline deoxofluorinating reagents. Org. Lett., 2009, 11(21), 5050-5053.
[http://dx.doi.org/10.1021/ol902039q] [PMID: 19799406]
[23]
Rathbone, E.B.; Wolard, G.R. A stereospecific synthesis of L-dendroketose derivatives. Carbohydr. Res., 1976, 46, 183-187.
[24]
Matsumura, Y.; Mori, N.; Nakano, T.; Sasakura, H.; Matsugi, T.; Hara, H.; Morizawa, Y. Synthesis of the highly potent prostanoid FP receptor agonist, AFP-168: a novel 15-deoxy-15,15-difluoroprostaglandin F2α derivative. Tetrahedron Lett., 2004, 45, 1527-1529.
[http://dx.doi.org/10.1016/j.tetlet.2003.12.029]
[25]
Yang, J.M.; Chen, C.C. GEMDOCK: a generic evolutionary method for molecular docking. Proteins, 2004, 55(2), 288-304.
[http://dx.doi.org/10.1002/prot.20035] [PMID: 15048822]
[26]
Komoto, J.; Yamada, T.; Watanabe, K.; Woodward, D.F.; Takusagawa, F. Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost. Biochemistry, 2006, 45(7), 1987-1996.
[http://dx.doi.org/10.1021/bi051861t] [PMID: 16475787]
[27]
Pettersen, E.F.G.T.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF-Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem., 2004, 25, 1605-1607.
[http://dx.doi.org/10.1002/jcc.20084] [PMID: 15264254]
[28]
Hsu, K.C.; Chen, Y.F.; Lin, S.R.; Yang, J.M. item dock: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinformatics, 2011, 12(Suppl. 1), S33.
[http://dx.doi.org/10.1186/1471-2105-12-S1-S33] [PMID: 21342564]
[29]
Cheedrala, R.K.; Sachwani, R.; Palakodety, R.K. Lipase mediated kinetic resolution of benzimidazolyl ethanols. Tetrahedron Asymmetry, 2008, 19, 901-905.
[http://dx.doi.org/10.1016/j.tetasy.2008.03.021]
[30]
Cheedarala, R.K.; Sunkara, V. Joon Won Park. Facile Synthesis of Second- Generation Dendrons with an Orthogonal Functional Group at the Focal Point. Synth. Commun., 2009, 39, 1966-1980.
[31]
Dubey, P.K.; Cheedarala, R.K.; Balaji, B. Solid phase synthesis of benzimidazole ketones and benzimidazole chalocones under solvent free conditions. Indian. J. Chem. Biol., 2003, 42B, 3128-3130.
[32]
Dubey, P.K.; Naidu, A.; Cheedarala, R.K. Studies on syntheses of 1-alkyl-2- substitutedthiazolylbenzimidazoles. Indian. J. Chem. Biol., 2003, 42B, 931-934.
[33]
Ramaiah, K.; Dubey, P.K.; Ramanatham, J.; Cheedarala, R.K.; Grossert, J.S. Benzimidazolium dichromates: Efficient reagents for selective oxidation of alcohols to carbonyl compounds. Indian. J. Chem. Br., 2003, 42B, 1765-1767.
[34]
Dubey, P.K.; Cheedarala, R.K.; Prasada, R.P.V.V. Synthesis of 1-alkyl -2- (substituted-2-pyridyl)benzimidazoles. Indian. J. Chem. Biol., 2003, 42B, 2115-2118.
[35]
Dubey, P.K.; Naidu, A.; Cheedarala, R.K.; Prasada, R.P.V.V. Preparation of 4- (1-alkyl-benzo[d]imidazole-2-yl)-2-phenyl-2,3 dihydrobenzo(b) [1,4] thiazepines Indian. J.Chem. Br., 2003, 42B, 1701-1705.
[36]
Dubey, P.K.; Kumar, R.; Cheedarala, R.K.; Hooper, D.L. Condensation of o-phenylenediamine with cinnamic acids. Synth. Commun., 2001, 31, 3439-3446.
[http://dx.doi.org/10.1081/SCC-100106202]
[37]
Park, S.J.; Cheedrala, R.K.; Diallo, M.S.; Kim, C.; Kim, I.S.; Goddard, W.A.J. Nanofiltration membranes based on polyvinylidene fluoride nanofibrous scaffolds and crosslinked polyethyleneimine networks. Nanopart. Res., 2012, 14, 884-887.
[http://dx.doi.org/10.1007/s11051-012-0884-7]

Rights & Permissions Print Cite
Article Metrics
37
2
© 2024 Bentham Science Publishers | Privacy Policy